Manitex Capital sells Valeo Pharma assets to Valeant for $25.3 mln

Canadian private investment firm Manitex Capital has sold the dermatology portfolio and several specialty product assets of its portfolio company Valeo Pharma Inc to Valeant Pharmaceuticals International Inc. The total consideration for the deal was $25.3 million, of which $18.3 million will be paid at closing and the balance over the next three years. Manitex, which has its headquarters in Kirkland, Québec, specializes in acquiring interests in emerging and established companies. At the time of the sale, it owned 40 percent of the Montréal-based Valeo.

DealsCanadaNorth AmericaBriefs